Minerva Neurosciences, Inc (NASDAQ:NERV) Receives Consensus Recommendation of "Reduce" from Brokerages

Key Points

• Minerva Neurosciences has a consensus “Reduce” rating from four analysts: two recommend selling, one recommends holding, and one recommends buying. The average 12-month price target is $10.33, compared with the stock’s recent price of $4.43.
• NERV shares have declined from a 52-week high of $12.46 and currently trade below both their 50-day and 200-day moving averages. Institutional investors own approximately 34.56% of the company.
• Minerva reported a quarterly loss of $0.14 per share, beating analyst expectations of a $0.19 loss. Analysts expect a full-year loss of approximately $0.73 per share as the clinical-stage biopharmaceutical company develops CNS therapies.

Shares of Minerva Neurosciences, Inc (NASDAQ:NERV - Get Free Report) have earned a consensus recommendation of "Reduce" from the four brokerages that are presently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and one has given a buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $10.3333.

Several research firms recently weighed in on NERV. Weiss Ratings reissued a "sell (d-)" rating on shares of Minerva Neurosciences in a research report on Wednesday, June 24th. Zacks Research downgraded Minerva Neurosciences from a "hold" rating to a "strong sell" rating in a research report on Wednesday, August 12th. Jefferies Financial Group raised shares of Minerva Neurosciences from a "hold" rating to a "mixed" rating and boosted their target price for the stock from $7.50 to $10.00 in a research report on Friday, August 14th. Finally, Wall Street Zen upgraded shares of Minerva Neurosciences from a "sell" rating to a "hold" rating in a research note on Saturday, August 8th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Janus Henderson Group PLC bought a new stake in Minerva Neurosciences in the fourth quarter valued at $36,000. OMERS ADMINISTRATION Corp bought a new position in shares of Minerva Neurosciences during the first quarter valued at $62,000. Cannon Global Investment Management LLC bought a new position in shares of Minerva Neurosciences in the first quarter valued at approximately $107,000. State Street Corp boosted its holdings in shares of Minerva Neurosciences by 45.4% in the 4th quarter. State Street Corp now owns 24,019 shares of the biopharmaceutical company's stock worth $97,000 after acquiring an additional 7,500 shares in the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of Minerva Neurosciences by 78,272.5% in the 1st quarter. Bank of America Corp DE now owns 39,970 shares of the biopharmaceutical company's stock worth $241,000 after acquiring an additional 39,919 shares in the last quarter. 34.56% of the stock is owned by institutional investors.

Minerva Neurosciences Stock Performance

NERV stock opened at $4.43 on Tuesday. The firm has a 50 day simple moving average of $4.52 and a 200 day simple moving average of $5.38. Minerva Neurosciences has a 52 week low of $1.93 and a 52 week high of $12.46. The stock has a market cap of $211.53 million, a P/E ratio of -0.15 and a beta of -0.08.

Minerva Neurosciences (NASDAQ:NERV - Get Free Report) last posted its earnings results on Friday, August 7th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.05. Sell-side analysts predict that Minerva Neurosciences will post -0.73 EPS for the current year.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company's research and development efforts are directed toward addressing unmet needs in psychiatric and neurological conditions, leveraging its expertise in neuropharmacology and receptor modulation. Minerva's goal is to bring forward differentiated molecules that can offer improved efficacy and safety profiles compared to existing treatments.

The company's most advanced programs include roluperidone (formerly MIN-101), which has been investigated for the treatment of negative symptoms of schizophrenia, and MIN-117, a novel serotonergic agent being evaluated in major depressive disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.